0001127602-22-027176.txt : 20221209
0001127602-22-027176.hdr.sgml : 20221209
20221209160714
ACCESSION NUMBER: 0001127602-22-027176
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221207
FILED AS OF DATE: 20221209
DATE AS OF CHANGE: 20221209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Klinger Shannon Thyme
CENTRAL INDEX KEY: 0001866132
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 221454835
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
STREET 2: SUITE 300
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2022-12-07
0001682852
Moderna, Inc.
MRNA
0001866132
Klinger Shannon Thyme
200 TECHNOLOGY SQUARE
SUITE 300
CAMBRIDGE
MA
02139
1
Chief Legal Officer
Common Stock
2022-12-07
4
M
0
1139
0
A
5262
D
Common Stock
2022-12-08
4
S
0
490
179.1496
D
4772
D
Restricted Stock Units
0
2022-12-07
4
M
0
1139
0
D
2022-06-07
Common Stock
1139
11386
D
Restricted stock units convert into common stock on a one-for-one basis.
Includes 174 shares acquired under the Moderna, Inc. 2018 Employee Stock Purchase Plan on November 30, 2022.
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive
plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
25% of the shares subject to this restricted stock unit award vested on June 7, 2022 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
/s/ Brian Sandstrom, as Attorney-in-Fact
2022-12-09